Mandating the Gardasil Vaccine: A Constitutional Analysis

Gardasil: Introducing the new human papillomavirus vaccine.

In 2006, the U.S. Food and Drug Administration (FDA) approved the first vaccine for prevention of cervical cancer based on the molecular biology of the disease. Gardasil (quadrivalent human papillomavirus [HPV] [types 6, 11, 16, and 18] recombinant vaccine, Merck & Co., Inc., Whitehouse Station, NJ) combats the common types of HPV responsible for cervical cancer precursor lesions. This article ...

The HPV vaccine market: Cervarix competes with Gardasil

Last month’s US FDA and WHO approval of CervarixTM, GlaxoSmithKline’s (GSK [London, UK]) vaccine against human papillomavirus (HPV) types 16 and 18 [101], boosted GSK’s position in the global HPV vaccine market. Gardasil, Merck’s vaccine against HPV types 6, 11, 16 and 18, obtained US FDA and WHO approvals in 2006. US FDA rejection of Cervarix 2 years ago, together with Cervarix’s lack of prote...

Merck hopes to extend gardasil vaccine to men.

G ardasil, the vaccine that protects women from common strains of the human papillomavirus (HPV) responsible for about 70% of cervical cancers, has proved successful. According to the Centers for Disease Control and Prevention’s National Immunization Survey, about 25% of women have received the vaccine. Now Merck, the pharmaceutical giant that manufactures Gardasil, is looking to match that suc...

Gardasil® - The New HPV Vaccine: The Right Product, the Right Time? A Commentary.

The federal and provincial governments have undertaken a universal immunization program to protect school-aged girls against cervical cancer using the new human papillomavirus vaccine Gardasil®. While the vaccine appears to be effective and safe, there are a number of important unanswered questions regarding it and the effects of the immunization program. Here we briefly review key literature a...

GARDASIL 9 (Human Papillomavirus 9-Valent Vaccine, Recombinant).